Avadel Pharmaceuticals plc
http://www.avadel.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Avadel Pharmaceuticals plc
Delisting Of Jazz’s Xyrem Patent In Orange Book Could Spur More Infringement Counterclaims
Jazz’s REMS patent on distribution of Xyrem does not belong in the Orange Book because it is directed to systems rather than a method of using the drug, court rules, agreeing with FTC’s analysis.
Ichnos’ Early-Stage Myeloma Asset Designed To Avoid ‘Pitfalls’ Of Magrolimab
Glenmark’s innovation subsidiary, Ichnos, highlights encouraging early data for lead bispecific antibody assets and hopes to accelerate these via licensing and partnership deals.The US-based arm also points to the tough biopharma financing market where investors are no longer satisfied with just the “preclinical story”.
Delisting Of Jazz’s Xyrem Patent In Orange Book Could Spur More Infringement Counterclaims
Jazz’s REMS patent on distribution of Xyrem does not belong in the Orange Book because it is directed to systems rather than a method of using the drug, court rules, agreeing with FTC’s analysis.
Keeping Track: Early Thanks Given By ImmunoGen, Provention Bio; More PD-1/L1 Combo Approvals
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Specialty Pharmaceuticals
- Vaccines
-
Drug Delivery
- Controlled Release
- Macromolecule
- Other Names / Subsidiaries
-
- Avadel Specialty Pharmaceuticals, LLC
- Éclat Pharmaceuticals, L.L.C.
- FSC Pediatrics, Inc.
- FSC Therapeutics, LLC
- FSC Laboratories, Inc.
- FSC Holdings, LLC
- Flamel Technologies